Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16

Benzinga Newsdesk www.benzinga.com Negative 71.0%

Neg 71% Neu 0% Pos 0%

Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $18 to $16.